{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:31:59Z","timestamp":1786480319961,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2026,2]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n We identify broad hyperactivity of the Janus kinase signal transducer and activator of transcription pathway in pediatric patients with FSGS as compared with healthy controls.<\/jats:p>\n <\/jats:list-item>\n \n \n We discover a distinct pattern of STAT3 hyperactivity in\n T<\/jats:italic>\n cell subsets, which correlates with worse clinical outcomes.\n <\/jats:p>\n <\/jats:list-item>\n \n We describe broad cytokine dysregulation corresponding with Janus kinase signal transducer and activator of transcription hyperactivity.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n FSGS accounts for approximately 20% of cases of pediatric nephrotic syndrome and is the leading cause of ESKD among glomerular disorders in the United States. Primary FSGS is thought to be caused by a circulating factor which causes podocyte, glomerular, and endothelial injury and immune dysregulation. There is growing evidence that the Janus kinase signal transducer and activator of transcription (JAK\/STAT) immunoregulatory pathway is involved in various kidney diseases; however, its role in FSGS has not been thoroughly studied. We recently identified JAK1 gain-of-function mutation in a pediatric patient with membranous nephropathy and multisystem immune dysregulation, which was successfully treated with a JAK inhibitor. We hypothesized that JAK\/STAT pathway hyperactivity may play a role in the pathogenesis of pediatric primary FSGS and may correlate with worse clinical outcomes.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We recruited eleven individuals age 2\u201318 years with primary FSGS and ten age- and sex-matched healthy controls. Mass cytometry with antibodies against STAT proteins was performed on heparinized whole blood samples to characterize JAK\/STAT pathway activity in immune cell subsets. Multiplex immunoassay was performed on plasma samples to quantify circulating cytokine levels. Unsupervised clustering by machine learning algorithms and statistical analyses were performed to determine clinically relevant patterns.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The JAK\/STAT pathway is overactive in 60% patients despite immunosuppression, predominantly showing increased phosphorylated STAT3 activity in\n T<\/jats:italic>\n cell subsets. The level of STAT3 phosphorylation in\n T<\/jats:italic>\n cells predicts lower kidney function, lower serum albumin, and increased proteinuria 1 year later. Various cytokines upstream of STAT3 phosphorylation are increased in patient plasma.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n JAK\/STAT pathway overactivity is present in pediatric patients with primary FSGS and predicts the severity of disease. JAK\/STAT hyperactivity is likely driven by cytokine signaling and may be targeted by JAK inhibition.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0000001010","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:00:17Z","timestamp":1763139617000},"page":"260-268","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Cytokine-Driven Janus Kinase Signal Transducer and Activator of Transcription Pathway Hyperactivity Predicts Disease Severity in Pediatric FSGS"],"prefix":"10.34067","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5036-7247","authenticated-orcid":false,"given":"Carol L.","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Cohen Children's Medical Center, New Hyde Park, New York"},{"name":"Center for Genetic Errors of Immunity, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1700-9162","authenticated-orcid":false,"given":"Ashley","family":"Richardson","sequence":"additional","affiliation":[{"name":"Center for Genetic Errors of Immunity, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4671-6349","authenticated-orcid":false,"given":"Marta","family":"Martin-Fernandez","sequence":"additional","affiliation":[{"name":"Center for Genetic Errors of Immunity, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9704-9756","authenticated-orcid":false,"given":"Louise","family":"Malle","sequence":"additional","affiliation":[{"name":"Center for Genetic Errors of Immunity, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7662-3851","authenticated-orcid":false,"given":"Sofija","family":"Buta","sequence":"additional","affiliation":[{"name":"Center for Genetic Errors of Immunity, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7247-0349","authenticated-orcid":false,"given":"Aum","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haylen","family":"Rosberger","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4572-6417","authenticated-orcid":false,"given":"Jean","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4319-5333","authenticated-orcid":false,"given":"Michael","family":"Horesh","sequence":"additional","affiliation":[{"name":"Center for Genetic Errors of Immunity, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8481-9210","authenticated-orcid":false,"given":"Jeffrey","family":"Saland","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Bogunovic","sequence":"additional","affiliation":[{"name":"Center for Genetic Errors of Immunity, Columbia University Medical Center, New York, New York"},{"name":"Department of Pediatrics, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"1","key":"B1-20260226","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0272-6386(00)70316-7","article-title":"Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia\/New Zealand: results from an international comparative study","volume":"35","author":"Maisonneuve","year":"2000","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B2-20260226","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/snep.2003.50025","article-title":"Trends in the epidemiology of focal segmental glomerulosclerosis","volume":"23","author":"Kitiyakara","year":"2003","journal-title":"Semin Nephrol."},{"issue":"9","key":"B3-20260226","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000508099","article-title":"Focal segmental glomerulosclerosis: state-of-the-art and clinical perspective","volume":"144","author":"Shabaka","year":"2020","journal-title":"Nephron."},{"issue":"5","key":"B4-20260226","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1172\/JCI36000","article-title":"Focal and segmental glomerulosclerosis induced in mice lacking decay-accelerating factor in T cells","volume":"119","author":"Bao","year":"2009","journal-title":"J Clin Invest."},{"key":"B5-20260226","doi-asserted-by":"crossref","first-page":"3765608","DOI":"10.1155\/2016\/3765608","article-title":"Circulating permeability factors in primary focal segmental glomerulosclerosis: a review of proposed candidates","volume":"2016","author":"K\u00f6nigshausen","year":"2016","journal-title":"Biomed Res Int."},{"issue":"6","key":"B6-20260226","doi-asserted-by":"crossref","first-page":"F1151","DOI":"10.1152\/ajprenal.00034.2019","article-title":"Targeting STAT3 signaling in kidney disease","volume":"316","author":"Pace","year":"2019","journal-title":"Am J Physiol Renal Physiol."},{"issue":"11","key":"B7-20260226","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ni.1656","article-title":"Priming for T helper type 2 differentiation by interleukin 2\u2013mediated induction of interleukin 4 receptor \u03b1-chain expression","volume":"9","author":"Liao","year":"2008","journal-title":"Nat Immunol."},{"issue":"5","key":"B8-20260226","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/ni.2025","article-title":"Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22","volume":"12","author":"Sonnenberg","year":"2011","journal-title":"Nat Immunol."},{"issue":"1","key":"B9-20260226","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ng.733","article-title":"Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease","volume":"43","author":"Momozawa","year":"2011","journal-title":"Nat Genet."},{"issue":"8","key":"B10-20260226","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/ng.3040","article-title":"Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease","volume":"46","author":"Flanagan","year":"2014","journal-title":"Nat Genet."},{"issue":"11","key":"B11-20260226","first-page":"1297","article-title":"JAK3 inhibition as a new concept for immune suppression","volume":"4","author":"Borie","year":"2003","journal-title":"Curr Opin Investig Drugs."},{"issue":"1","key":"B12-20260226","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MNH.0000000000000079","article-title":"JAK inhibition and progressive kidney disease","volume":"24","author":"Brosius","year":"2015","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"1","key":"B13-20260226","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ki.2009.98","article-title":"Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy","volume":"76","author":"Lu","year":"2009","journal-title":"Kidney Int."},{"issue":"9","key":"B14-20260226","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.2337\/db10-1181","article-title":"Transcriptome analysis of human diabetic kidney disease","volume":"60","author":"Woroniecka","year":"2011","journal-title":"Diabetes."},{"issue":"11","key":"B15-20260226","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol Dial Transplant."},{"issue":"7","key":"B16-20260226","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1681\/ASN.2011050442","article-title":"Kidney injury accelerates cystogenesis via pathways modulated by heme oxygenase and complement","volume":"23","author":"Zhou","year":"2012","journal-title":"J Am Soc Nephrol."},{"issue":"19","key":"B17-20260226","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.1073\/pnas.1103816108","article-title":"Polycystin-1 regulates STAT activity by a dual mechanism","volume":"108","author":"Talbot","year":"2011","journal-title":"Proc Natl Acad Sci."},{"issue":"44","key":"B18-20260226","doi-asserted-by":"crossref","first-page":"18067","DOI":"10.1073\/pnas.1111966108","article-title":"Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease","volume":"108","author":"Olsan","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"issue":"7","key":"B19-20260226","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/QAD.0b013e32835f1ea1","article-title":"Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1-associated nephropathy","volume":"27","author":"Gu","year":"2013","journal-title":"AIDS."},{"issue":"11","key":"B20-20260226","doi-asserted-by":"crossref","first-page":"e157432","DOI":"10.1172\/jci.insight.157432","article-title":"JAK inhibitor blocks COVID-19 cytokine-induced JAK\/STAT\/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids","volume":"7","author":"Nystrom","year":"2022","journal-title":"JCI Insight."},{"issue":"7","key":"B21-20260226","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2215\/CJN.11010919","article-title":"JAK-STAT activity in peripheral blood cells and kidney tissue in IgA nephropathy","volume":"15","author":"Tao","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B22-20260226","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.trsl.2015.03.002","article-title":"Janus kinase 2\/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier","volume":"166","author":"Sharma","year":"2015","journal-title":"Translational Res J Lab Clin Med."},{"issue":"1","key":"B23-20260226","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.kint.2021.10.041","article-title":"A glomerular transcriptomic landscape of apolipoprotein L1 in Black patients with focal segmental glomerulosclerosis","volume":"102","author":"McNulty","year":"2022","journal-title":"Kidney Int."},{"issue":"3","key":"B24-20260226","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.immuni.2020.07.006","article-title":"Complex autoinflammatory syndrome unveils fundamental principles of JAK1 kinase transcriptional and biochemical function","volume":"53","author":"Gruber","year":"2020","journal-title":"Immunity."},{"issue":"5","key":"B25-20260226","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/cyto.a.24317","article-title":"A streamlined whole blood CyTOF workflow defines a circulating immune cell signature of COVID-19","volume":"99","author":"Geanon","year":"2021","journal-title":"Cytometry A."},{"issue":"4","key":"B27-20260226","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.kint.2018.05.022","article-title":"JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis","volume":"94","author":"Tao","year":"2018","journal-title":"Kidney Int."},{"issue":"3","key":"B28-20260226","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating primary, genetic, and secondary fsgs in adults: a clinicopathologic approach","volume":"29","author":"De Vriese","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"B29-20260226","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat Rev Immunol."},{"issue":"7","key":"B30-20260226","doi-asserted-by":"crossref","first-page":"e0157907","DOI":"10.1371\/journal.pone.0157907","article-title":"Activation of the IL-2 receptor in podocytes: a potential mechanism for podocyte injury in idiopathic nephrotic syndrome?","volume":"11","author":"Zea","year":"2016","journal-title":"PLoS One"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:03:35Z","timestamp":1786478615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000001010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000001010","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"2025-06-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}